

RUTH BLATT MERKATZ, PhD, RN, FAAN
89 Greenhaven Road
Rye, New York 10580
phone 917-670-5784 (mobile)
e-mail: rmerkatz@popcouncil.org; rmerkatz@gmail.com

EDUCATION

DEGREE/YEAR

Cornell University, Ithaca, NY
Cornell University—The New York Hospital School of Nursing
New York, NY

BS, RN - 1961

Frances Payne Bolton School of Nursing,
Case Western Reserve University
Cleveland, Ohio

MS - 1977

Adelphi University, School of Nursing
Garden City, Long Island, NY

PhD - 1989

PROFESSIONAL EMPLOYMENT

Surgical Staff Nurse
The New York Hospital, New York, NY

1961 – 1962
1965 - 1966

Camp Nurse
Camp HES, Bear Mountain, New York

1966

Nurse Instructor
The New York Hospital, Lying-In Division, New York, NY

1966 - 1970

Clinical Nurse Specialist (Maternal/Child Health)
(Clinical Care & Staff Education/Parent Education & Counseling;
The New York Hospital, Lying-In Division, New York, NY

1970 - 1973

Nurse Clinician

1976 - 1982

Postpartum Nursing; University Hospitals of Cleveland
MacDonald House, Cleveland, Ohio

Assistant Director of Nursing: Nurse Clinician-Maternal/Child &
& Women's Health/Nurse Researcher
The Jack D. Weiler Hospital of the AECOM: MMC
Albert Einstein College of Medicine

1982 - 1990

Director of Nursing (Acting)
The Jack D. Weiler Hospital of the Albert Einstein College of Medicine/
Montefiore Medical Center (MMC), New York, NY

1990 – 1991

Special Assistant to the Commissioner:
Women's Health Issues

1991 – 1994

U.S. Food and Drug Administration—Department of
Health and Human Services, Washington, DC

Director, Office of Women's Health 1994 - 1996
U.S. Food and Drug Administration—Department of
Health and Human Services, Washington, DC
(Established the Office & Mission- ongoing today)*

Director/Team Leader, Pfizer Women's Health; 1997 – 2005
Pfizer Pharmaceuticals Group, Pfizer Inc, New York, NY

Project Director, Contraceptive Development, Population Council 2005 - 2007

Director, Clinical Development, Reproductive Health 2007 - Present
Population Council

ACADEMIC APPOINTMENTS

Clinical Instructor 1976 - 1979
Maternity Nursing-University Hospitals of Cleveland
Frances Payne Bolton School of Nursing, Case Western Reserve University

Assistant Clinical Professor 1979 - 1983
Frances Payne Bolton School of Nursing
Case Western Reserve University, Cleveland, Ohio

Adjunct Lecturer 1982 - 1986
Lehman College of the City University of New York

Clinical Assistant Professor 1989 - 1995
Department of Obstetrics & Gynecology and Women's Health
Albert Einstein College of Medicine

Clinical Associate Professor 1995 - Present
Department of Obstetrics & Gynecology and Women's Health
Department of Epidemiology and Social Medicine
Albert Einstein College of Medicine

Adjunct Professor, Division of Nursing 1997 - 2000
New York University

Clinical Professor 2015-Present
Department of Obstetrics & Gynecology and Women's Health
Albert Einstein College of Medicine

POLITICAL APPOINTMENTS

Westchester County Board of Health 2001 - Present

PROFESSIONAL SOCIETY MEMBERSHIPS (Current)

American Academy of Nursing

American Nurses Association (New York State Chapter)
Association of Women's Health, Obstetric, and Neonatal Nurses
Association of Reproductive Health Professionals
Sigma Theta Tau (Alpha Upsilon Chapter)

LICENSURE

New York Nursing Registration ID # 157030-1 Current
Ohio Nursing Registration ID # 21-13-4921
Washington, DC License ID # 58611

DISTINCTIONS

Sigma Theta Tau 1965
National Nursing Honorary Society

Helen Bunge Award for Nursing Research: 1977
Frances Payne Bolton School of Nursing
Case Western Reserve University

Award for Excellence in Nursing: 1977
Frances Payne Bolton School of Nursing
Case Western Reserve University

Certificate of Recognition for Contributions to the Community: 1982
Federation for Community Planning, Cleveland, Ohio

Bolton Award for the Professional Member Making an
Outstanding Contribution to the Community: 1982
Junior League of Cleveland, Ohio

FDA Commissioner's Special Citation for Contributions to the 1992
Scientific and Policy Issues Associated with Breast Implants
May, 1992

FDA Commissioner's Special Citation for Exceptional Skill and 1993
Commitment in Successfully Changing FDA Policy to Allow Women
of Childbearing Potential to Participate in Early Phase Drug Trials
May, 1993

Distinguished Alumnus Award: May, 1994
Cornell University-The New York Hospital School of Nursing

FDA Commissioner's Special Group Citation May, 1995
for Outstanding Service to the National AIDS Drug
Development Task Force

FDA Commissioner's Special Group Citation for
Establishing the Mammography Information Service
May, 1995

Fellow of the American Academy of Nursing November, 1995

FDA Commissioner's Special Citation for Outstanding December, 1995

Leadership and Vision in Establishing the Office of Women's Health

Distinguished Alumnus Award Adelphi University; School of Nursing	May, 1996
FDA Commissioner's Special Citation for Outstanding Contributions to the Women's Health Program of the FDA	January, 1997
Athena Award Partnership for Women's Health Columbia University	February, 1999
Honoree, International Health Awareness Network	March, 1999
Career Achievement Award: Assoc of Women's Health, Obstetrics & Neonatal Nursing	June, 2002
Best in Class, Top Scientific Research - Internationals Family Planning Research Conference, International Conference on Family Planning, Addis Ababa, Ethiopia; Sponsored by B & M Gates Foundation & Johns Hopkins University School of Public Health	November 15, 2013
Case Western Reserve Univ. Graduation Speaker- Frances Payne Bolton School of Nursing	December 5, 2014

RESEARCH/GRANT SUPPORT

Long-term Follow-up of High Risk Mothers, Infants and Families. The Robert Wood Johnson Foundation	1978 – 1981
The Effects of Frequency and Duration of Early Breast-Feeding on Development of Nipple Soreness, Milk Output, Infant Serum Bilirubin, and Infant Well-Being on the Longevity of Nursing. University Hospitals of Cleveland Fund	1980 - 1983
Doctoral Dissertation: The Influence of Maternal Attachment and the Capacity for Empathy on Perception of Social Support among Pregnant Minority Women. Grant Support - Sigma Theta Tau	1989
Co- Principal Investigator & Technical Coordinator: Development of a new contraceptive vaginal ring with Nestorone® & Ethinyl estradiol (Phase 3 trial) <u>USAID</u> Cooperative Agreement; PO-A-00-04-00019- Population Council Product Development;	9/05 – 6/31/09 7/09-6/14

Acceptability of a Contraceptive Vaginal Ring: Supplementary study within
RO1 project **3RO1HD047764-02S2**, Assessing & Improving the Measurement

of Sexual Behavior; NIH/NICHD. [Co-Investigator](#)

9/05– 5/12

Co-Principle Investigator: Delivering Contraceptive Vaginal Rings: Annual Program Statement No. SOL-OAA-13-000024: Agreement No. USAID-OAA-A-13-00075 Family Planning & Reproductive Health to Address Unmet Need

10/13-9/18

ADDITIONAL CERTIFICATION

American Society for Psychoprophylaxis in Obstetrics
New York, NY

1969 - 1991

The National Certification Board of Diabetes Educators
Certified Diabetes Educator (CDE)

1986 – 2000

BOARD AFFILIATIONS

The National Certification Board of Diabetes Educators
Certified Diabetes Educator (CDE)

1986 – 2000

President's Council of Cornell Women- Cornell University

1995 – Present

Friends of the Institute of Nursing Research

1999 - 2005

Jacobs Institute of Women's Health

1999 – 2005

Westchester County Board of Health

2002- Present

New York Hall of Science

2004 – 2007

Scientific Advisory Committee- International Partnership for

2006- Present

Rosalind Franklin Society, Founding Board Member

2007- Present

International Partnership for Microbicides (IPM) Scientific Advisory Board
Chair- IPM/USAID Project Advisory Committee (PAC)

2009-Present
2014- Present

PROFESSIONAL & COMMUNITY ACTIVITIES AND AFFILIATIONS

Editor, Cornell Alumni News (School of Nursing)

1965 – 1968

Member, New York State Democratic Party

1965 – 1973
1992- Present

Committee to Recreate St. Catherine's Park,
NYC Steering and Planning Committee

1968 - 1973

Chairperson, Women's Program, American Congress on
Fertility and Sterility, New York City

1971

New York Junior League

1973

Cleveland Junior League	1973 - 1982
Western Reserve Historical Society, Docent	1973 - 1974
"Friends to New Mothers"; Proposer and Advisor to new program for Maternal and Infant Care Project of Cleveland	1974 - 1976
Mercer School Parent Teachers Association; Parent Aide Shaker Heights, Ohio	1976 - 1978
Editorial Advisory Board, <u>The Female Patient</u> .	1976 - 1978
Chairperson, Committee for Early Detection and Prevention of Child Abuse/Neglect; Federation for Community Planning Cleveland, Ohio	1977 - 1982
Chairperson, Healthy Baby Month, Sponsored by Cleveland Chapter, March of Dimes	1977
Committee for Children at Risk, Member under Federation for Community Planning, Cleveland, Ohio	1978 - 1982
Co-Chairperson, Institute on Children at Risk: The Home, School and Community, Cleveland, Ohio	1978
Coach "Crash Course in Childhood" developed by Dr. Ray Helfer, Cleveland, Ohio	1978 - 1979
Co-Chairperson, Parenting Disorders in Pediatric Settings Sponsored by Cleveland Regional Perinatal Network and Cleveland Council on Children at Risk	1979
Chairperson, Volunteer Program to Provide Support to New Mothers: Mac Donald House University Hospitals of Cleveland	1980 - 1982
New York City Steering Committee on Breast-Feeding New York State Department of Health	1983 - 1991
Nominating Committee, Rye Neck Board of Education	1985 - 1988
Bronx Community Child Abuse Task Force	1985 - 1991
Advisory Board Member, Prevention Intervention Research Center (PIRC), Albert Einstein College of Medicine Bronx Breast Feeding Project	1986 - 1991
Human Rights Commission Member, Rye, New York.	1986 -1991
Co-Chairperson, Bioethics Committee Weiler Division/Montefiore Medical Center.	1987 - 1991

Nurse Consultant American International Perinatal Health, Inc.	1989
Education Chairperson, Mid Hudson Valley Region New York State Perinatal Association	1989 - 1991
Editorial Advisory Board, <u>Obstetrics and Gynecology</u>	1989 – 1995
Member, Women's Health Coordinating Committee, <u>U.S. Public Health Service</u>	1991 - 1997
Member, Surgeon General's Committee for Women and Children with AIDS; <u>U.S. Public Health Service</u>	1991 – 1997
Editorial Advisory Board, <u>Journal of Women's Health</u>	1992 - Present
Member, Consumer Education Committee, <u>NAACOG</u> .	1992 - 1993
Member, Breast Implant Research Task Force, <u>US Public Health Service</u>	1992
Member, DHHS Inter-Agency Working Group on Breast and Gynecologic Cancer, <u>US Public Health Service</u> .	1993 - Present
Invited Member, President's Council of Cornell Women; (Chair -Special Task Force on Health of Cornell Students)	1995 - Present 1999-2001
Contributing Member-National Action Plan on Breast Cancer <u>US Public Health Service</u> .	1993 - 1995
Member, Planning Group under National Plan on Breast Cancer to Implement a Comprehensive Plan to Address the Needs of Individuals Carrying Breast Cancer Susceptibility Gene(s), <u>US Public Health Service</u>	1994
Editorial Advisory Board, <u>American Journal of Public Health</u> .	1994 - 1995
Program Chair, FDA Regulated Products and Pregnant Women; Arlington, VA	11/7 – 8/1994
Member, Human Subject Regulation Drafting Committee To Revise Subpart B, CFR, Part 46 Additional DHHS Protections Pertaining to Research for Pregnant Women, Human Fetuses Member, Human Subject Regulation Drafting Committee; US DHHS	1994-1995
Board Member- Jacobs Institute of Women's Health	1995-2003
Board Member, Friends of the National Institute of Nursing Research- NIH	2002-2006
Program Co-Chair, FDA Regulated Products and Pregnant	11/7-8/1994

Women, US FDA, Crystal City, VA	
Program Co-Chair, Gender Studies in Product Development: Scientific Issues and Approaches; US FDA, Rockville, MD	11/6-7/1995
Invited Participant, "Beyond Hunt Valley: Research in Women's Health for the 21 st Century, Scientific Meeting Sponsored by the Office of Research on Women's Health of the National Institutes of Health; Philadelphia, Pa., Santa Fe, NM, Bethesda, MD	9/25-26/96
Volunteer, HIV Law Project, NYC	1998 - 2003
Special Task Force on Nursing Shortage, City University of NY	2001
Institute of Medicine Reviewer: Exploring the Biological Contributions To Health: Does Sex Matter?	2001
Institute of Medicine Committee Member: New Frontiers in Contraception: A Blueprint for Action	2003 - 2004

EINSTEIN AND POPULATION COUNCIL TEACHING ACTIVITIES

Conference Director: <i>Autumn in New York</i> "Women's Health Across the Lifespan" Department of Obstetrics & Gynecology Albert Einstein College of Medicine Bronx, NY	11/14-15, 1993
Participant/Speaker: <i>Autumn in New York</i> "A Commitment to Equity in Women's and Perinatal Health: Closing the Gaps" Department of Obstetrics & Gynecology and Women's Health Albert Einstein College of Medicine Bronx, NY	11/15-16/2003
Journey to Uganda- Grand Rounds Lecture* (sparked Departmental Interest among Faculty and students to embark upon teaching and service in selected SSA countries	10/11/ 2005
Organizing Committee: <i>Autumn in New York</i> "Women's Health: A Global Perspective In Honor of Allan Rosenfield, MD" Department of Obstetrics & Gynecology and Women's Health Albert Einstein College of Medicine Bronx, NY	11/10-12/2006
Director, Mentor Population Council's Family Planning Teaching/Learning Program offered semi-annually to Selected Family Planning Fellows training under US Family Planning Fellowship Program Mentored 10 Family Planning Fellows	2009-present

Bixby Fellowship Mentor (Population Council) Mentor to Dr. Yongmei Huang
(International Peace Maternity and Child Health Hospital: Shanghai Institute of
Family Planning Technical Instruction

10/10-8/13

Program Committee: *Autumn in New York*
"Local and Global Health Issues of Adolescent Girls"
Department of Obstetrics & Gynecology and Women's Health
Albert Einstein College of Medicine
Bronx, NY

11/19/2013

Fellowship Director for Research
Family Planning Fellowship
Department of Obstetrics and Gynecology & Women's Health
Albert Einstein College of Medicine (Assisted in preparation of Einstein fellowship application and site
Visit in 2014; Fellowship status awarded to Dept. of Obs and GYN & Women's Health
July 2014.

2014-present

Mentored Dr. Carol Sales Vieira- FP fellowship at Population Council;
Sponsored by Medical School of Ribeirao Preto, University of Sao Paulo, Brazil

Sept 2016-Jan 2018

ORIGINAL COMMUNICATIONS IN REVIEWED JOURNALS

1. Smith E, Veolitze M, **Merkatz R.** Social aspects of abortion counseling for patients undergoing elective abortion. ClinObstet Gynecol 1971 Mar; 14(1): 204-16.
2. **Merkatz R,** Smith E, Seitz R. Preoperative teaching for gynecologic patients. Am J Nurs 1974 June; 74(6) 1072-4.
3. **Merkatz RB.** Budd K. Merkatz IR. Psychological and social implications of scientific care for pregnant diabetic women. Sem in Perinatol 1978 October; 11(4):373-81.
4. DeCarvalho M. , Robertson S. Klaus M. **Merkatz RB.** The effects of frequency and duration of breast feeding on serum bilirubin, weight gain and milk output. Ped Res. 1981. 15. 530; doi 0.1203/00006450-198104001-00552
5. DeCarvalho M. Klaus MH. **Merkatz RB.** The effects of frequency of breast-feeding on serum bilirubin concentration. Am J Dis Child 1982 Aug; 136: (8):737-8.
6. Pittard WB. **Merkatz R.** Fletcher BD. Radioactive excretion in human milk following administration of technetium TC-99m macroaggregated albumin. Pediatrics, 1982 Aug; 70(2):231-4.
7. DeCarvalho M. Robertson S. **Merkatz RB.** Klaus MH. Milk intake and frequency of feeding in breast-fed infants. Early Hum Dev 1982 Nov; 7(2):155-63.
8. Anderson D. Williams F. **Merkatz RB.** Schulman P. Kerr D. Pittard W. Length of gestation and nutritional components of human milk. Am J Clin Nutr 1983 May; 37(5):810-14.
9. Langer O. Levy J. Brustman L. Anyaegbunam A. **Merkatz RB.** Divon M: Glycemic Control in GDM - How tight is tight enough: Sga vs lga. Am J Obstet Gynecol 1989 Sep; 161(3): 646-53.

10. **Merkatz RB** & Merkatz IR: The contribution of the nurse and the machine in home uterine monitoring systems. Am J Obstet Gynecol 1991 May; 164(5Pt1):1159-1162.
11. Mikhail MS. Freda MC. **Merkatz RB**. Polizzotto R. Mazloon E. Merkatz IR. The effect of fetal movement counting on maternal attachment to fetus. Am J Obstet Gynecol 1991 October; 165(4Pt1):998-991.
12. **Merkatz RB** & Couig MP. Helping America take its medicine. Am J Nurs 1992 June; 92(6):59-62.
13. **Merkatz RB**. Bagley GP. McCarthy EJ. A qualitative analysis of self reported experiences among women encountering difficulties with silicone breast implants. J WOM Health 1993 Summer; 2(2):105-9.
14. McCarthy EJ. **Merkatz RB**. Bagley GP. A descriptive analysis of physical complaints from women with silicone breast implants. J WOM Health 1993 Summer; 2(2): 111-15.
15. **Merkatz RB**. Temple R. Sobel S. Feiden K. Kessler DA. Women in clinical trials of new drugs and biologics: A change in FDA policy. N Engl J Med. 1993 July; 329(4):292-296.
16. Kessler DA. **Merkatz RB**. Shapiro R. A call for higher standards for breast implants. JAMA 1993 Dec 1; 270(21):2607-8.
17. **Merkatz RB**. FDA: Making a difference in women's health. J Am Med Wom Assoc 1994 July/Aug; 49(4):117-120.
18. **Merkatz RB**. White Junod S. Historical background of changes in FDA policy on the study and evaluation of drugs in women. Acad Med 1994 Sept; 69(9):703-707.
19. Sherman LA. Temple R. **Merkatz RB**. Women in clinical trials: An FDA perspective. Science. Aug 11, 1995; 269:793-5.
20. **Merkatz RB**. Inclusion of women in clinical trials: A Historical overview of scientific, ethical, and legal issues. JOGNN. 1998 Jan/Feb; 27(1): 001-7
21. **Merkatz RB**. Female Sexuality: Scientific Advances- Editorial. JWH. May 2002; 11(4): 331-3
22. **Merkatz RB**. FDA's Office of Women's Health- Will it Endure. JWH August 2007; 16(6):818-826.
23. **Merkatz RB**, Tokay B, Sitruk-Ware RL. Methods for female contraception: A model for innovation in drug delivery systems. Clin Pharmacology & Therapeutics. May 2009 85 (5): 553-7.
24. Huang YM, **Merkatz R**, Kang JZ, Roberts K, Hu XY, Di Donato F, Sitruk-Ware R, Cheng LN. Postpartum unintended pregnancy and contraception practice among rural-to-urban migrant women in Shanghai. Contraception. 2012 Dec; 86(6):731-8.
25. RamaRao S, Clark H, **Merkatz R**, Sussman H, Sitruk-Ware R. Progesterone vaginal ring: introducing a contraceptive to meet the needs of breastfeeding women. Contraception 2013 Nov; 88(5), 591-8). doi: 10.1016/j.contraception.2013.05.004. Epub 2013 May 16
26. Huang YM, **Merkatz R**, Zu, Zuu, Roberts K, F, Sitruk-Ware R, Cheng LN. The free perinatal/postpartum contraceptive services project for migrant women in Shanghai: Effects on the incidence of unintended pregnancy. Contraception 2014 June; 89 (6) 521-7.

27. **Merkatz RM**, Plagianos M, Hoskin E, M, Hewett P, Mensch B. Contraception. Acceptability of the Nestorone®/Ethinyl Estradiol Contraceptive Vaginal Ring; Development of a Model; Implications for Introduction. *Contraception*. 90 (5) 2014, 514–21.
28. Huang Y, Jensen JT, , Brache V, Cochon L, Williams A, Miranda MJ, Croxatto H, Kumar N, Sussman H, Hoskin E, Plagianos M, Roberts R, **Merkatz R**, Blithe D, Sitruk-Ware R. A randomized study on pharmacodynamic effects of vaginal rings delivering the progesterone receptor modulator ulipristal acetate: research for a novel estrogen-free, method of contraception. *Contraception*. 90 (6) 2014, 559-622.
29. Brache V, **Merkatz R**, Kumar N, Jesam C, Sussman H, Hoskin E, Roberts K, Alami M, Taylor D, Jorge A, Croxatto H, Lorange E, Mishell DR, Sitruk-Ware R. A dose-finding, cross-over study to evaluate the effect of a Nestorone®/Estradiol transdermal gel delivery on ovulation suppression in normal ovulating women. *CONTRACEPTION* Epub 2015 May 29
30. Huang T, **Merkatz RB**, Hillier SL, Roberts K, Blithe DL, Sitruk-Ware R, Creinin, MD. Effects of a One Year Reusable Contraceptive Vaginal Ring on Vaginal Microflora and the Risk of Vaginal Infection: An Open-Label Prospective Evaluation. *PLOS ONE*. Aug 14, 2015, DOI 10.1371, journal pone 0134460.
31. Archer DF, Thomas MA, Conard J, **Merkatz RB**, Creasy GW, Roberts K, Plagianos M, Blithe D, Sitruk-Ware R. Impact on Hepatic Estrogen-Sensitive Proteins by a One-Year Contraceptive Vaginal Ring Delivering Nestorone® and Ethinyl Estradiol. *Contraception*. 2015 doi:10.1016/j.15.09.008.
32. Sitruk-Ware R, Ramarao S, **Merkatz R**, Townsend J. Risk of Pregnancy in Breastfeeding Mothers: Role of the Progesterone Vaginal Ring on Birth Spacing. 2016. *EMJ Repro Health*. 2(1): 66-72
33. Stifani BM, Plagianos B, Sales Vieira C, **Merkatz RB** Factors associated with non-adherence to instructions for using the Nestorone®/ethinyl estradiol contraceptive vaginal ring. *Contraception* 2018 May;97(5):415- 421. doi: 10.1016/j.contraception.2017.12.011
34. Simmons K, Kumar N, Plagianos M, Roberts K, Hoskin E, Alami M, Creasy G, Variano B, **Merkatz R**. Effects of concurrent vaginal miconazole treatment on the absorption and exposure of Nestorone® (segesterone acetate) and ethinyl estradiol delivered from a contraceptive vaginal ring: A randomized, crossover drug-drug interaction study. Published online: October 30, 2017. <http://doi.org/10.1016/j.contraception.2017.10.010>
35. Archer DF, **Merkatz RB**, Bahamondes L, Westhoff CL, Darney P, Apter D, Jensen JT, Brache V, Nelson AL, Banks E, Bartfai G, Portman DJ, Plagianos M, Dart C, Kumar N, Creasy GW, Sitruk-Ware R, Blithe DL. Efficacy of the 1-Year (13-Cycle) Segesterone Acetate/Ethinyl Estradiol Contraceptive Vaginal System: Results from Phase 3 Trials, Published online June 20, 2019, [http://dx.doi.org/10.1016/S2214-109X\(19\)30265-7](http://dx.doi.org/10.1016/S2214-109X(19)30265-7)
36. Murphy DJ, McCoy CF, Plagianos. M, RamaRao S, **Merkatz R**, Clark H, Boyd P, Variano. Malcom RK. Post-use ring weight and residual drug content as potential objective measures of user adherence to a contraceptive progesterone vaginal ring. 24-JUN-2019 DOI information: 10.1016/j. Contraception.2019.06.013
37. Vieira CS, Fraser I, Plagianos M, Burke AE, Westhoff CL, Jensen JT, Brache V, Bahamondes L, **Merkatz RB**, Sitruk-Ware R, Blithe DL. Bleeding profile associated with

1-year use of the segesterone acetate/ethinyl estradiol contraceptive vaginal system: pooled analysis from phase 3 trials. In Press. Contraception

ADDITIONAL PUBLICATIONS

1. **Merkatz, Ruth B.** Breast-Feeding Information. The New York Hospital. Unpublished Patient Information, 1972.
2. **Merkatz, Ruth B.** Behavioral responses of hospitalized high risk maternity patients. Unpublished Masters' Thesis, Case Western Reserve University, Cleveland, Ohio, 1976.
5. **Merkatz, Ruth B.;** Lytle, Nancy. Nursing of women in the age of liberation. Dubuque, Iowa: Wm. C. Brown; 1977. Chapter 7, Modern trends in parenting.
6. ***Merkatz, Ruth B.** et al. Parenting disorders: Identification and Intervention with families at risk. Cleveland: Federation for Community Planning & The Cleveland Regional Perinatal Network; Nov. 1977. * **City of Cleveland Merit Award.**
7. **Merkatz RB.** Prolonged hospitalization of pregnant women: The effects on the family. Birth 1978; 5(4):204-206.
8. **Merkatz, Ruth B.** Proceedings of Centennial Celebration of Cornell University, New York: The New York Hospital School of Nursing; 1978. Behavioral responses of hospitalized high risk maternity patients.
9. ****Merkatz, Ruth B.** Budd, Karen. Merkatz Irwin R.; In Merkatz, Irwin R. Adam, Peter AJ. (Eds) The Diabetic Pregnancy: A Perinatal Perspective. New York: Grune and Stratton; 1979. Chapter 7, Psychological and Social Implications of Scientific Care for Pregnant Diabetic Women. ** **Annual Book of the Year Award, American Journal of Nursing, 1979.**
10. **Merkatz Ruth B.** et al. Parenting disorders: Identification and intervention with families at risk. Cleveland: Federation for Community Planning. (expanded edition) Nov. 1980.
11. **Merkatz Ruth B** & Budd K. in Smith ED (Ed.). Teaching and the obstetrical and gynecologic patient. New York: Appleton-Century-Crofts, 1981. Chapter 4, The high risk patient: A new challenge in maternity nursing.
10. Merkatz, Irwin R. **Merkatz, Ruth B.** The Proceedings of Second Annual Women's Health Day. University Hospitals of Cleveland, April 1981. Healthy Pregnancy and Parenthood in the 80's.
11. **Merkatz, Ruth B.** & DeFlorville, Wendy. Mothers' Guide to Breast-Feeding. Cleveland: Maternity Nursing Department, University Hospitals of Cleveland; 1978. Revised, 1981.
12. **Merkatz, Ruth B;** Kennell, John H. Klaus, Marshall H. Parent-infant bonding. St. Louis: C.V. Mosby, 1982. Critical Comments.
13. **Merkatz, Ruth B.;** Smalkowski, S.F. Readings in public policy and health care. Garden City, NY: Adelphi University, Summer, 1984. Ethical dilemmas in reproductive health following Roe v. Wade.
14. **Merkatz, Ruth B.** et al; Breastfeeding guidelines for the hospital. New York: New York City Steering Committee for the Promotion of Breastfeeding, June, 1984.

15. **Merkatz, Ruth B.** The Influence of maternal attachment and the capacity for empathy on perception of social support among pregnant minority women. Doctoral Dissertation, Adelphi Univ. UMI Dissertation Abstracts International, No. 3266, University Microfilms, Ann Arbor, MI, 1989.
16. **Merkatz, Ruth B.;** Cherry, Sheldon H. Merkatz, Irwin R. Medical, surgical and gynecologic complications of pregnancy. 4th ed. Baltimore: Williams & Wilkins; 1991. Chapter 14, Psychosocial issues in high risk pregnancy.
17. **Merkatz RB.** Gel-filled breast implants: an update. *Contemp Ob/Gyn* 1992 June; 61-75.
18. **Merkatz RB** & Couig, MP. Women's health: FDA nears decision on breast implants. *Am J Nurs* 1992 Jan; 92(1): 11-12.
19. **Merkatz RB.** & Couig MP. From FDA Nurses. *Am J Nurs* Nov, 1992:74-80; Feb, 1993: June, 1993: 72-76.
20. **Merkatz RB.** Letter: The breast implant controversy. *N Engl J Med*, 1993 Jun 18; 326(25):1695-6.
21. **Merkatz RB.** Women in clinical trials of new drugs and biologics: A change in FDA policy. *Food Drug Law J*, 1993 Summer; 48(2): 292-96.
22. Couig MP & **Merkatz RB.** From FDA Nurses. MEDWatch: The New Medical Products Reporting Program, *Am J Nurs* August, 1993, 65-8.
23. **Merkatz RB.** From FDA Nurses: Progress Notes on Women's Health notes on women's health, *Am J Nurs* November, 1993, 75-80.
24. Kessler DA. **Merkatz RB.** Temple R. Reply: FDA policy on women in drug trials. *N Engl J Med* 1993 Dec 9; 329(24):1815-6.
25. Kessler DA. **Merkatz RB.** Shapiro R. A call for higher standards for breast implants. *JAMA* 1993 Dec 1; 270(21):2607-8.
26. **Merkatz RB.** Summers EI. Toigo TA. FDA: Making a difference for women and HIV/AIDS. *JAMWA* 1995 50(3):108:121.
27. Merkatz IR. & **Merkatz RB.** (Eds). Social interventions in Perinatology. *Sem Perinatol* 1995 19(4):241-340.
28. **Merkatz RB.** Helping women control their lives. *MCN* 1996 21(1):39-40.
29. **Merkatz RB.** FDA moves ahead with policies on studying drugs' effects on women. *Reg Affairs Focus.* 1996(10):20-21.
30. **Merkatz RB.** Gender analysis in peer reviewed journals: A call to publishers. *JWH* 1996 5(6):525-7.
31. **Merkatz RB,** Clary CM, Harrison W. Women and Mental Health Research Methodology: In Kornstein SG, Clayton AH (Eds) *Womens' Mental Health.* Guilford Publications, Inc. New York. 2001 (Copyright 2002).

32. Institute of Medicine: New Frontiers in Contraceptive Research: a Blueprint for Action. Sharyl J. Nass & Jerome F. Strauss III, Editors. **Committee Member**- 2004.
33. **Merkatz RB**, Summers E. Nursing's Influence on Drug Development and Safety. In Mason, DJ, Leavitt, JK, Chaffeen MW (Eds.). (2011). Policy and politics in nursing and health care. Philadelphia, PA. Elsevier.
34. Roberts K, **Merkatz RB**, Sales Vieira C. Letter to the Editor- N Engl J Med, March 29, 2018; 378: 1263-1266, DOI 10.1045/NEJMc1800054

ABSTRACTS

1. Anderson D., Kerr, D., Pittard, W., Schulman, P., **Merkatz, R.**, et al. Comparative Nutrient Composition of Human Milk. Pediatric Research, April, 1981, Vol. 15, p. 507.
2. **Merkatz R**, Villeneuve M, O'Kane G: Psychological Characteristics of Pregnant Diabetic Women. American Diabetes Assoc. Jan. 1986.
3. Mikhail, M.S., Freda, M., Polizzotto R., Mazloom E., **Merkatz R.B.**, and Merkatz I.R. Does Fetal Movement Counting Increase Maternal Fetal Attachment? Society of Perinatal Obstetricians. 1991;164: p. 232.
4. **Merkatz, R.** Sitruk-Ware, R. Sivin, I. Mensch, B. Hewett, P. Cooney, M. Hoskin, E. Development and Acceptability of the NES/EE CVR: A Year-Long, User Controlled Contraceptive Method. International Conference on Family Planning. Munyonyo, Uganda, Nov. 2009.
5. **Merkatz, R.** Sussman, H. Sivin, I. Mensch, B. Hewett, P. Cooney, M. Sitruk-Ware, R. Phase III Investigators. Preliminary results from a phase III study on the nestorone®/ethinyl estradiol contraceptive vaginal ring: A new, long acting (one year) user controlled contraceptive method. 11th Congress of the European Society of Contraception and Reproductive Health, The Hague, May 2010.
6. **Merkatz, R.** Sitruk-Ware, R. Mishell, D. Brache, V. Taylor, D, Jesam Gaiete, C. A dose-finding, cross-over study to evaluate the effect of a transdermal Nestorone®- Estradiol (NES/E2) gel on ovulation suppression and assess acceptability in healthy ovulating women. 66th Annual Meeting of the American Society for Reproductive Medicine, Denver, CO, October 25, 2010.
7. **Merkatz, R.** Fisher, A. Cooney, M. Huang, Y. Hoskin, E. Mensch, B. and Investigators from 12 Clinical Sites. Acceptability of the Nestorone®/Ethinyl Estradiol Contraceptive Vaginal. Ring. North American Forum on Family Planning, Washington, DC. October 24, 2011.
8. Townsend, J. Sitruk-Ware, R. **Merkatz, R.** Gabelnick, HL. Glasier, A Translating Contraception Research to Product Delivery; Better semi long-acting methods: Acceptability of new contraceptives in development. International Conference on Family Planning, Dakar, Senegal, Nov 30, 2011.
9. **Merkatz, R.** Mishell, D. Holger, K. Brache, V. Jesam C. Hoskin, E. Sitruk-Ware, R. A Phase II, Dose-Finding, Crossover Study to Evaluate the Effect of a Transdermal Nestorone®/Estradiol (NES/E2 Gel on Ovulation Suppression and Assess Acceptability in Healthy Ovulating Women. International Conference on Family Planning, Dakar, Senegal, Nov 30, 2011.
10. **Merkatz, R.** Family Planning for the Postpartum Lactating Mother. International Conference on Reproductive Health with Emphasis on Strategies for Family Planning and the 22nd Annual Meeting of the Indian Society for the Study of Reproduction & Fertility. February 19-21, 2012.

11. **Merkatz R**, K. Roberts, H. Sussman, E. Hoskin, R. Sitruk-Ware, D. Apter, I. Bahamondes, E. Banks, G. Bartfai, V. Brache, H. Croxatto, P. Darney, I. Frasier, K. Gemzell Danielsson, M. Gilliam, M. Miranda, D. Mishell, A. Nicosia, D. Portman, J. Steinauer, and E. Weisberg. Efficacy, Safety & Acceptability of a New Contraceptive Vaginal Ring Delivering Nestorone® 150 µg & Ethinyl Estradiol 15µg daily: Results from a Multi-Center Open Label Phase 3 Clinical Trial. First global conference on contraception, reproductive & sexual health Copenhagen, Denmark, May 22, 2013.
12. **Merkatz, R**. Plagianos, M. An Acceptability Model for the Nestorone®/Ethinyl Estradiol Contraceptive Vaginal Ring. International Conference on Family Planning, Addis Ababa, Ethiopia, Nov 15, 2013 (Awarded Best in Class, Scientific Research).
13. Manning J, VanBirglen F, Bukusi R, **Merkatz R**. From Bench to Bedside Bench to Bedside: Public, Private, Regional and Donor Perspectives on the Challenges and Opportunities for Introducing New Contraceptives- A Preformed Panel: Donaldson R (Moderator) - 2013 International Conference on Family Planning- Ethiopia.
14. **Merkatz R**, Townsend, J, Sailer J, Creasy G, Sussman H, Kumar N, Variano B, RamaRao S, Sitruk-Ware R. Development of the Nestorone®/Ethinyl Estradiol Contraceptive Vaginal Ring (NES/EE CVR); Challenges, Opportunities and Obligations for the Public Sector. Poster Presentation- European Society for contraception. Lisbon, May 29-31, 2014.
15. Creasy G, Brache V, Croxatto H, Mishell D, Kumar N, Roberts K, **Merkatz R**, Sitruk-Ware R. User controlled long acting reversible contraception: the pharmacokinetic profile of the Nestorone®/Ethinyl Estradiol Contraceptive Vaginal Ring. European Society for contraception. Lisbon, May 29-31, 2014.
16. **Merkatz R**, Huang Y, Hillier S, Blithe D, Roberts K, Creinin M. Effects of a one year reusable contraceptive vaginal ring on vaginal flora and vaginal infection: A prospective evaluation. European Society for Contraception. Lisbon, May 29-31, 2014.
17. **Merkatz R**. Townsend, J, Sailer J, Creasy G, Sussman H, Kumar N, Variano B, RamaRao S, Sitruk-Ware R. Development of the Nestorone®/Ethinyl Estradiol Contraceptive Vaginal Ring (NES/EE CVR); Challenges, Opportunities and Obligations for the Public Sector. Poster Presentation- European Society for contraception. Lisbon. May 29-31, 2014.
18. Mishell, D, Kumar, N, **Merkatz, R**, Creasy, G, Roberts, K, Sitruk-Ware, R. Maximum Concentration and Exposure to Ethinyl Estradiol from the Nestorone®/Ethinyl Estradiol Contraceptive Vaginal Ring (NES/EE CVR) Poster accepted for presentation @ Society for Reproductive Investigation 62nd Annual Scientific Meeting San Francisco, March 25-28 2015.
19. **Merkatz R**. Efficacy, Safety and Acceptability of a New Contraceptive Vaginal Ring Delivering Nestorone® 150 µg & Ethinyl Estradiol; Results form an Open Label Phase 3 Clinical Trial. Figo Meeting. XXI FIGO World Congress of Gynecology & Obstetrics from October 4 - 9, 2015. Vancouver, Canada. Global Obstetrics & Gynecology.
20. **Merkatz R**. Acceptability of the Nestorone®/Ethinyl Estradiol Contraceptive Vaginal Ring; Development of a Model: Implications for Introduction. XXI FIGO World Congress of Gynecology & Obstetrics from October 4 - 9, 2015. Vancouver, Canada. Global Obstetrics & Gynecology.
22. Plagianos M, Stifani B, Sales-Vieira C, **Merkatz R**. Sales-Vieira C. Acceptability & Adherence To Use Of The Nestorone®/Ethinylestradiol Contraceptive Vaginal Ring: Comparison of Audio Computer-Assisted Self-Interviews and Face To Face Interviews, ASRM, Denver, Sept.2018

23. **Merkatz R**, Roy M, Plagianos M, Hazra A, Sales Vieira C, Rijo N, Sitruk Ware R. Reports of Acceptability by Women Using Novel Contraceptive Vagina. Rings in Diverse Settings. 15th ESC Congress, Budapest, Hungary, May 9-12 2018.
24. **Merkatz R**. Creasy B, Blithe D, Archer D, Gemzell K; Sitruk-Ware R. Clinical Trial Results for the Segesterone Acetate (SA/EE) Contraceptive Vaginal Ring: A New Long-Acting Contraceptive Under a Woman's Control. International Conf on Family Planning, Kigali, Rwanda, Nov 2018
25. Plagianos M, **Merkatz R**, Do women really tell us what they think of new contraceptives? What we can learn from various interviewing techniques.
26. Westhoff C, Darney P, Jensen JT, Bahamondes L, Apter L, **Merkatz RB**. Efficacy of the 1- Year Segesterone Acetate/Ethinyl Estradiol Contraceptive Vaginal System. American College of Obstetrics and Gynecology (**ACOG**), May 3-6, 2019, Nashville, TN.
27. **Merkatz RB**, Magnani M, Sussman H, Creasy GW, Sitruk-Ware R. Efficacy and Safety of a 1-Year Segesterone Acetate/Ethinyl Estradiol Contraceptive Vaginal System. American Academy of Nurse Practitioners (**AANP**), Jun 18-23, 2019 Indianapolis, IN
28. **Merkatz RB**, Magnani M, Sussman H, Creasy GW, Sitruk-Ware R. Efficacy and Safety of a 1-Year Segesterone Acetate/Ethinyl Estradiol Contraceptive Vaginal System. Association of Women's Health, Obstetrical and Neonatal Nurses (AWHONN), Jun 8- 12, 2019, Atlanta, GA
29. Archer DF, Sitruk-Ware R, Mirkin S, Brache V, **Merkatz RB**. Low Systemic Levels of Segesterone Acetate are Required to Inhibit Ovulation in Women. Endocrine Society, Mar 23-26, 2019, New Orleans, LA
30. Archer DF, Thomas MA, Sitruk-Ware R, Liu J, Bernick B, Mirkin S, **Merkatz RB**, Kumar N, Blithe DL. A Novel 1-Year Contraceptive Vaginal System Delivering Segesterone Acetate and Ethinyl Estradiol: Effects on Lipids and other Hepatic Proteins. Endocrine Society, Mar 23-26, 2019, New Orleans, LA.

PRESENTATIONS: Historical Selections of Oral Presentations Prior to 1990

1. Preoperative Counseling of the Gynecologic Patient. The Nurses Association of the American College of Obstetrics and Gynecology, Annual Convention, New York City, 1972.
2. Predictors of Child Abuse. Case Western Reserve University Medical School, December 1977 sponsored by the Council on Children at Risk and the Cleveland Regional Perinatal Network. December, 1977.
3. Hospital Policies That Promote Breast-Feeding Success: A Research Approach. Bronx Lebanon Hospital, Department of Obstetrics, July 8, 1983.
4. The Nurses' Role in Supporting the Breast-Feeding Family During the Pregnancy Cycle. Lincoln Hospital, Department of Nursing, September 28, 1984.
5. Increasing the Incidence of Breast Feeding in the U.S.; National Conference of Child Health sponsored by Bureau Maternal/Child Health, Washington, DC, October 14, 1983.

6. Nursing Care Policies That Promote Successful Breast Feeding in the Hospital Setting. Mt. Sinai Hospital, Department of Obstetrical Nursing, New York, New York, April 25, 1984.
7. A Comprehensive Health Professional's Approach to Promoting Breast Feeding. New York City Conference sponsored by Steering Committee to Promote Breast Feeding New York, New York, June 4, 1984.
8. Mothering Behaviors and Child Development Outcomes: A Longitudinal Study Comparing High Risk and Low Risk Mothers. Research Day, Hospital of the Albert Einstein College of Medicine, Bronx, New York, June 14, 1984.
9. Medical Factors Associated with Preterm Birth. March of Dimes Annual Nursing Conference, New York City, March 6, 1987.
10. Psychological and Social Factors in the Management of Diabetes in Pregnancy: Critical Issues in Diabetes in Pregnancy, The Albert Einstein College of Medicine, Department of Obstetrics and Gynecology, November, 1987.
11. Nurses Working in Government. Guest Lecture in Honor of Nurse Recognition Week, Flushing Hospital, May 11, 1993.

Selected Oral Presentations/Teaching Lectures 1990-Present

12. The Effects of Maternal Attachment and the Capacity for Empathy on Social Support. The Society of Psychosomatic Obstetrics & Gynecology, New York City, March 29, 1990.
13. Avoiding Moral Distress in Caring for the Dying Oncology Patient. Oncology Nursing Society, Hudson Valley Chapter, February 7, 1990.
14. Utilizing the POPRAS Record; A Guide to Prenatal Care. New York City Hospitals Seminars for Perinatal Nurses, sponsored by the March of Dimes, New York Chapter, June 7, 1990.
15. Development of a Model for Social Support among Black and Hispanic Pregnant Women. Sigma Theta Tau, Alpha Upsilon Chapter, January, 1991.
16. A Women's Health Initiative at FDA. Washington, DC. Annual Meeting of FDA Public Affairs Specialists, October, 1991.
17. A Model for the Development of Social Support among Black and Hispanic Pregnant Women. Sigma Theta Tau International Conference, Orlando, Florida, November, 1991.
18. **Keynote Address:** Participation of Women with AIDS in Clinical Trials. Annual Meeting, Community Groups for Women and Aids, Washington DC. January, 1992.
19. Research Initiatives in Women's Health. University of Michigan School of Nursing, Ann Arbor, Michigan. March 19, 1992.
20. **Keynote Address:** The Challenge of Promoting Women's Health. Women's Health Conference, Texas Medical Center, Houston; Sponsored by FDA, USHHS, & Texas Agricultural Extension Service, March 20, 1992.

21. **Keynote Address:** An FDA Agenda for Women's Health. North American Menopause Society. Cleveland, Ohio, September 16, 1992.
22. **Keynote Address:** Women in Clinical Trials; An Overview. Keynote Address, Conference sponsored by USFDA and Food, Drug and Law Institute on Women in Clinical Trials of FDA-Regulated Products-Who Participates and Who Decides, Washington, DC, October 5, 1992.
23. FDA Approval of Depo-Provera. CBS Morning Show, October 30, 1992.
24. The Role of the FDA in Safeguarding Patient Care. Grand Rounds, Department of Obstetrics and Gynecology at the Albert Einstein College of Medicine, December 22, 1992.
25. FDA Calls for Changes in Contraceptive Labeling. CBS Morning Show, April 9, 1993.
26. Participation of Women in Clinical Trials of New Drugs. Pharmaceutical Manufacturers Association, Newark, NJ, April 16, 1993.
27. Nurses Working in Government. Guest Lecture in Honor of Nurse Recognition Week, Flushing Hospital, May 11, 1993.
28. Plenary Address: Women's Issues-Lessons Learned from the Breast Implant Story. Public Health Service, Commissioned Officers Association Annual Meeting, Scottsdale, AZ., May 24, 1993.
29. Women in Clinical Trials: The FDA's Historical Concern and Its Recent Developments. NIH Conference on Women and Minorities in Clinical Research, Georgetown University, Washington, DC, June 28, 1993.
30. FDA's New Policies on Women in Clinical Trials. Hearing on Recruitment and Retention of Women into Clinical Trials; Office for Research on Women's Health, NIH, Bethesda, MD, July 13, 1993.
31. The Mammography Quality Standards Act (MQSA): Consumer Concerns. FDA Conference, Implementing the MQSA of 1992: Roles in Improving Mammography Services, September 21, 1993, Reston, VA.
32. **Keynote Address:** Women's Health: An Historical Perspective. Keynote Address, Women's Health across the Lifespan, Annual Autumn in NY Conference sponsored by the Department of Obstetrics & Gynecology, Albert Einstein College of Medicine, November 14, 1993.
33. Participation of Women in Clinical Trials; Lecture to the Department of Epidemiology and Social Medicine; Albert Einstein College of Medicine; February 7, 1994.
34. Women's Health Comes of Age; FDA Seminar presented at the Annual Meeting of the American College of Obstetricians and Gynecologists, Orlando, FL. May 11, 1994.
35. Recent FDA and NIH Perspectives on Women's Participation/Access into Clinical Research vs. Scientific Objectives. Association of Clinical Pharmacology Units; 6th Annual Meeting, Chicago, Ill. October 7, 1994.
36. **Keynote Address:** Promoting Health in Women with Turner's Syndrome. Keynote Address; Annual Meeting, Turners Syndrome Society. San Diego, CA, October 9, 1994.
37. Testing FDA Medical Products in Pregnant Women: Is it Time to Change?

Introductory Address. Conference on FDA Regulated Products in Pregnant Women. Sponsored by the Office of Women's Health, US Food and Drug Administration, Crystal City, VA. November 7-8, 1994.

38. Eighteen Months since the New Gender Guideline. Speech to the Corporate Advisory Council of the Society for the Advancement of Women's Health Research, Washington, DC, January 19, 1995.
39. Women's Health: Its Role in the Women's Movement. Linnea Henderson Nursing Lectureship, Kent State University, Kent, Ohio, April 6, 1995.
40. Women and Drug Research Trials, Women's Wellness Conference to the New York State Legislature, sponsored by the American College of Obstetricians and Gynecologists, NY State, Albany, NY, May 22, 1995.
41. Women's Health at the FDA: A New Era- Speech to the Jacob's Institute of Women's Health, July 3, 1995.
42. Including Women in Clinical Trials. Luncheon Speech to Ohio Congress on Women's Health sponsored by Ohio Department of Health and Ohio State University. Columbus, Ohio, September 10, 1995.
43. Current Issues in Clinical Trials for Pharmaceuticals: 19th Annual Conference Regulatory Affairs Professional Society, Washington, DC, October 12, 1995.
44. Clinical Trials: Inclusion of Women. Sixth International Congress on Ethics in Medicine, New York Academy of Medicine, New York City, October 24, 1995.
45. Clinical Research and Products Liability Issues: Including Women with Childbearing Potential in Drug Trials. New York State Bar Association, New York City, October 30, 1995.
46. Historical Review of Women's Participation in Clinical Trials: Opening Remarks at FDA sponsored workshop on Gender Studies in Product Development: Scientific Issues and Approaches. Rockville, MD, November 6, 1995.
47. Inclusion of Women in Clinical Trials: New Developments Since the 1993 FDA Guideline; National Institutes of Health, Bethesda, MD, February 22, 1996.
48. Scientific Aspects of Including Women in Clinical Trials: Drugs Directorate of Canada, Ottawa, Canada, April 2, 1996.
49. Celebrating Nursing: Our Past, Present and Future: Montefiore Medical Center, Bronx, NY, May 9, 1996.
50. Women's Health Advances through Clinical Trials: Third Annual Women's Health Conference, Society for the Advancement of Women's Health Research, Washington, DC. June 18, 1996.
51. Women and HIV: Impact on Policies for Participation of Women in Clinical Trials. Duke University School of Law Conference on HIV Law & Policy: Ensuring Gender-Equitable Reform, Durham, NC, February 21, 1997.
52. Are any Drugs Safe for Use in Pregnancy? Annual March of Dimes Nursing Conference, New York City February 27, 1997.
53. Women's Health Comes of Age, US Public Health Service Nursing Research Conference, Bethesda, MD March 21, 1997.

54. Are any Drugs Safe for Use in Pregnancy: Status of Current Information, World Conference in Perinatology, Rome, Italy May 8-9, 1997.
55. Continuing Controversy on Mammography for Women Ages 40-49 Years, The National Council on Women's Health, Lenox Hill Hospital, New York, NY, June 12, 1997.
56. Cancers in Women: A Reassessment on Focus, 5th Annual Congress on Women's Health, Washington, DC. June 25, 1997.
57. The Art of Women's Health: Women's Healthcare and Wellness Conference, Washington, DC. September 10, 1997.
58. Recruitment and Retention of Minorities and Women in Cancer Clinical Trials, University of Illinois, Chicago, IL September 19, 1997.
59. Addressing Women's Health Issues in a Managed Care Environment; IPA Association of America, Washington, DC, October 20, 1997.
60. Women's Health Leadership Conference; Blue Cross and Blue Shield Association, Communicating Success to Women, Boston, MA, October 31, 1997.
61. Why Women's Health Matters, Women for Healthcare Education Reform and Equity (WHERE) First Anniversary Celebration, Seattle, WA, November 3, 1997.
62. Report to the Commission on Women-Commonwealth Foundation Conference, Washington, DC; November 12, 1998.
63. To Your Health, Madame, The New York Women's Agenda, May 15, 1998.
64. Heart Disease and Women, Washington Hospital Center, January 15, 1999.
65. The Changing Face of Women's Health, Introductory Remarks; Maryland Science Center, Baltimore; March, 1999.
66. From Seneca Falls to Women's Health, commemorating the 150th anniversary of the signing of the Declaration of Sentiments, Seneca Falls, NY, July, 1999.
67. **Keynote Speech:** Beijing +5 Conference on Women: "Health Issues for Women: A Global Perspective", United Nations Headquarters, NY; June 8, 2000.
68. Women's Health in the New Millennium: Focus on Mental Health; New York University Medical Center, Department of Psychiatry; September 17, 2000.
69. Developing Leadership for Women's Health: A Look at Changing Policies at the FDA; Society for Women's Health Research, Medical Health Advisory Board; Washington, DC, October 25, 2000.
70. History of Gender-Based Medicine and Future Directions - University of Kentucky Medical School Grand Rounds, April 17, 2001.
71. The Prime of Our Lives: An Innovative Women's Health Education Program; Dept. of Obs/Gyn & Women's Health Grand Rounds; Dec 3, 2002.

72. Women's Health-The Model Has Shifted; US Congressional Briefing Sponsored by the Jacobs Institute of Women's Health; May 13, 2004.
73. Journey to Uganda: Personal Reflections: Department of Ob/Gyn- Grand Rounds, Sept 20, 2005.
74. The Role of the FDA in Ensuring Safety of Drug Therapy: Grand Rounds, Dept. of Ob/Gyn, Lenox Hill Hospital, November, 9, 2005.
75. Presentations to the International Committee on Contraceptive Research (ICCR) (2005-2018-Supplement available on Request).
76. Development and Acceptability of the NES/EE CVR: A Year-Long, User Controlled Contraceptive Method. International Conference on Family Planning, Sponsored by the Bill & Melinda Gates Foundation. Uganda, Nov. 2009.
77. Phase III Investigators. Preliminary results from a phase III study of the nesterone®/ethinyl estradiol contraceptive vaginal ring: A new, long acting (one year) user controlled contraceptive method. 11th Congress of the European Society of Contraception and Reproductive Health. The Hague, May 2010.
78. A dose-finding, cross-over study to evaluate the effect of a transdermal Nestorone®- Estradiol (NES/E2) gel on ovulation suppression and assess acceptability in healthy ovulating women. 66th Annual Meeting of the American Society for Reproductive Medicine. Denver, CO, October 25, 2010.
79. Acceptability of the Nestorone®/Ethinyl Estradiol Contraceptive Vaginal. Ring. North American Forum on Family Planning, Washington, DC. October 24, 2011.
80. Translating Contraception Research to Product Delivery; Better semi long-acting methods: Acceptability of new contraceptives in development. International Conference on Family Planning. Dakar, Senegal, Nov 30, 2011.
81. A Phase II, Dose- Finding, Crossover Study to Evaluate the Effect of a Transdermal. Nestorone®/Estradiol (NES/E2 Gel on Ovulation Suppression and Assess Acceptability in Healthy Ovulating Women. International Conference on Family Planning, Sponsored by Sponsored by the Bill & Melinda Gates Foundation. Dakar, Senegal, Nov 30, 2011.
82. Family Planning for the Postpartum Lactating Mother. International Conference on Reproductive Health with Emphasis on Strategies for Family Planning and the 22nd Annual Meeting of the Indian Society for the Study of Reproduction & Fertility. February 19-21, 2012.
83. Efficacy, Safety & Acceptability of a New Contraceptive Vaginal Ring Delivering Nestorone® 150 µg & Ethinyl Estradiol 15µg daily: Results from a Multi-Center Open Label Phase 3 Clinical Trial. First global conference on contraception, reproductive & sexual health. Copenhagen, Denmark, May 22, 2013.
84. Plenary Session: An Acceptability Model for the Nestorone®/Ethinyl Estradiol Contraceptive Vaginal Ring. International Conference on Family Planning, Sponsored by the Bill & Melinda Gates Foundation. Addis Ababa, Ethiopia, Nov 15, 2013 (Awarded best in class scientific paper).
85. From Bench to Bedside: Public, Private, Regional and Donor Perspectives on the Challenges and Opportunities for Introducing New Contraceptives- A Preformed Panel: Donaldson R (Moderator) - 2013 International Conference on Family Planning. Ethiopia.

86. User controlled long acting reversible contraception: the pharmacokinetic profile of the Nestorone®/Ethinyl Estradiol Contraceptive Vaginal Ring. European Society for contraception. Lisbon, May 29-31, 2014.
87. Effects of a one- year reusable contraceptive vaginal ring on vaginal flora and vaginal infection: A prospective evaluation. European Society for Contraception. Lisbon, May 29-31, 2014.
89. Advancing Development of Multipurpose Prevention Technologies to Reduce Unintended Pregnancy and Acquisition of Sexually Transmitted Infection, ICFP- Kigali, Rwanda, Nov 2018
90. Discovery, Development, Delivery:A New Long-Acting Contraceptive Under a Woman's Control/ Grand Rounds, Albert Einstein College of Medicine, Montefiore Medical Center, Dec. 18, 2019.

U.S. CONGRESSIONAL TESTIMONIES AND BRIEFINGS

1. Breast Implant Update. Briefing before Committee on Energy and Commerce, US House of Representatives, October 24, 1991.
2. Breast Implant Update. Briefing before Women's Congressional Caucus, US Congress, October 31, 1991.
3. The Breast Implant Moratorium. Briefing before Energy and Commerce and Committee, US House of Representatives, January 6, 1992.
4. FDA Testimony on the Status of Women's Health. Before the Subcommittee on Regulation, Business Opportunities, and Technology: Committee on Small Business; US House of Representatives, May 8, 1992.
5. Women's Health Issues at FDA. Briefing before Subcommittee on Agriculture, Rural Development, Food & Drug Administration & Related Agencies, Committee on Appropriations, US House of Representatives, May 5, 1993.
6. Tamoxifen Update. Briefing for Congressional Staff on new information on Tamoxifen; Its use for treatment and prevention of breast cancer. U.S. House of Representatives, April 11, 1994.
7. Creation of the Office of Women's Health at FDA. Briefing for selected members of U.S. House of Representatives, November 16, 1994.
8. Creation of the Office of Women's Health at FDA. Briefing for selected members of U.S. Senate, November 17, 1994.
9. FDA Testimony on Breast Implants and Medical Devices. Before the Human Resources and Intergovernmental Affairs Subcommittee of the House Government Reform and Oversight Committee, U.S. House of Representatives, August 1, 1995.
10. FDA Office of Women's Health Update. Briefing for Selected House Members and Staff. May 23, 1996.